Feldan Therapeutics has developed a patented peptide-based technology platform.
Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of the unique characteristics of the Shuttle.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 18, 2022 | Grant | — | 1 | — | — | Detail |
Oct 12, 2018 | Grant | $2M | 1 | National Institutes of Health | — | Detail |
Sep 18, 2018 | Series A | $13.80M | 4 | GC | — | Detail |
Sep 28, 2011 | Seed | — | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |
GC | Yes | Series A |
Cystic Fibrosis Foundation | — | Grant |
AQC Capital | — | Series A |
Asahi Kasei Corporate Venture Capital | — | Series A |
Stonebridge Ventures | — | Series A |
FIER Succes | — | Seed |
Anges Quebec | — | Seed |